Humanwell Healthcare Unit Gets China Clinical Trial Approval for Seizure Treatment

MT NewswiresFeb 28 00:00 ET

Humanwell Healthcare Subsidiary Gets Approval for Pain Relief Clinical Trials

MT NewswiresFeb 27 23:51 ET

Humanwell Healthcare (600079.SH): RFUS-301 injection has received the approval notice for clinical drug trials.

Gelonghui, February 27 | Humanwell Healthcare (600079.SH) announced that its holding subsidiary, Yichang Humanwell Pharmaceutical Co., Ltd., recently received the clinical trial approval notice for the RFUS-301 injection issued by the National Medical Products Administration. The RFUS-301 injection is a modified postoperative analgesic developed by Yichang Humanwell. Currently, there are no similar products on the domestic market. So far, Yichang Humanwell has accumulated an investment of about 10 million yuan in research and development for this project.

Gelonghui FinanceFeb 27 03:52 ET

Humanwell Healthcare Obtains Registration for Pain Management Drug; Shares Up 3%

MT NewswiresFeb 26 22:46 ET

Humanwell Healthcare (600079.SH): The hydrochloride spray has obtained a pharmaceutical registration certificate.

On February 26, Gelonghui reported that Humanwell Healthcare (600079.SH) announced that its holding subsidiary, Yichang Humanwell Pharmaceutical Co., Ltd. (referred to as 'Yichang Humanwell', in which the company holds 80% of the shares), recently received the 'Pharmaceutical Registration Certificate' approved and issued by the National Medical Products Administration for the hydrochloride of Tapentadol tablets. Hydrochloride of Tapentadol tablets is used for treating acute pain in adult patients who require opioid medication and for whom alternative therapy does not adequately relieve.

Gelonghui FinanceFeb 26 03:39 ET

Sinolink: Focus on innovative growth in pharmaceutical investment for 2025, with a dual approach of "AI + Innovative Drugs."

In traditional medicine, policy expectations are anticipated to reverse and performance pressure may soon show a turnaround. Seize the opportunities of Innovative Drugs expanding overseas and the increased volume in the domestic market, as well as the recovery opportunities in the left-side Sector stocks.

Zhitong FinanceFeb 16 22:01 ET